Clichy

• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors: … Recruiting
  2024-519505-35-00 5 2026-02-02 hepatocellulaR carcinoma
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) Recruiting
  2024-514400-14-00 4 2026-01-23 liver transplanted patients with advanced hepatocellular carcinoma
• A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease Recruiting
  2025-521398-15-00 5 2025-12-04 Immune system diseases
• Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and H … Recruiting
  2025-521178-33-00 4 2025-12-03 Chronic Hepatitis B Virus Infection
• Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with … Recruiting
  2024-519048-33-00 10 2025-11-25 resected pancreatic adenocarcinoma
• TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PAT … Recruiting
  2024-520029-35-01 4 2025-11-17 ADVANCED BILIARY TRACT CARCINOMA
• Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients. Recruiting
  2024-514912-28-00 10 2025-10-22 Patients with hepatocellular carcinoma with high tumor burden.
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting
  2024-519875-24-00 5 2025-09-26 Carcinoid syndrome
• Evaluation of Multiparametric dynamic whole-body 68Ga-PSMA PET imaging for Hepatocellular Carcinoma recurrence. HIMIKO study. Recruiting
  2024-515178-28-00 9 2025-09-23 Hepatocellular carcinoma
• Effect of long-term carvedilol to prevent decompensation or death in patients with asymptomatic Child-Pugh A5 to B8 cirrhosis and clinically … Recruiting
  2024-511663-28-00 6 2025-09-11 Asymptomatic Child-Pugh A5 to B8 cirrhosis
• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 5 2025-09-08 Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
• A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta I … Recruiting
  2024-517167-23-00 5 2025-08-28 Chronic Hepatitis D Infection
• Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting
  2024-515875-36-00 4 2025-08-18 Advanced biliary tract cancer (BTC)
• Lu177-Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors Recruiting
  2024-517921-14-00 9 2025-05-07 Neuroendocrine tumors of midgut origin
• Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial Recruiting
  2023-506512-40-00 5 2025-04-16 Acute Kidney Injury
• Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation Recruiting
  2023-506601-19-00 6 2025-04-15 transplantation
• MAINTAIN-POP: EXL01 and prevention of post-operative recurrence of Crohn's disease Recruiting
  2024-511357-22-00 4 2025-03-31 Crohn's disease
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• HALT : Influence of Human Albumin supplementation on kidney dysfunction after Liver Transplantation Recruiting
  2024-514804-14-00 6 2025-03-26 Liver transplantation
• MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER” Recruiting
  2023-508201-25-00 4 2025-03-12 Hepatocellular carcinoma

Showing 49–72 of 182 trials